Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Haim Leibovitzh, Shadi Nayeri, Krzysztof Borowski, Cristian Hernandez-Rocha, Sun-Ho Lee, Williams Turpin, Joanne M Stempak, Iqbaljit Sandhu, Raquel Milgrom, Michelle I Smith, Kenneth Croitoru, Gideon M Hirschfield, Aliya Gulamhusein, Mark S Silverberg
BACKGROUND: Primary sclerosing cholangitis associated with inflammatory bowel disease (IBD-PSC) carries significant morbidity compared to IBD without PSC. Alterations in microbial composition and bile acid (BA) profiles have been shown to modulate chronic inflammation in IBD, but data in IBD-PSC is scarce. We aimed to assess the differences in gut microbiome composition as well as in the BA profile and BA-related microbial functions between IBD-PSC and IBD-only. METHODS: 54 IBD-PSC and 62 IBD-only subjects were enrolled from 2012 to 2021...
July 9, 2024: Journal of Crohn's & Colitis
#2
JOURNAL ARTICLE
Ruth de Francisco, Isabel Pérez-Martínez, Andrés Castaño-García, Lorena Carballo-Folgoso, Pablo Flórez-Díez, Cristina García-Pérez, Emilia Fernández-González, Valeria Rolle, Valentina Chiminazzo, Rubén Queiro, Sara Alonso-Castro, Jorge Santos-Juanes, Miguel Gueimonde, Sabino Riestra
BACKGROUND AND AIMS: The association of inflammatory bowel disease (IBD) with other immune-mediated inflammatory diseases (IMIDs) in the same patient is well known. We aimed to evaluate the degree of knowledge that patients with IBD have regarding the coexistence of other IMIDs and to analyze the factors associated with the concordance between self-reported and confirmed medical information. METHODS: Patients with IBD at a tertiary hospital answered a questionnaire on the presence of 54 IMIDs (self-reported diagnosis), and their IMID diagnosis was confirmed in their medical records (reference diagnosis)...
July 9, 2024: Journal of Crohn's & Colitis
#3
JOURNAL ARTICLE
Chih-Wen Huang, Hsu-Heng Yen, Yang-Yuan Chen
BACKGROUND AND AIMS: Approximately 40% of patients with steroid-refractory acute severe ulcerative colitis (steroid-refractory (SR) ASUC) requires colectomies. Advanced therapies may reduce the short-term colectomy rates in patients with SR ASUC. However, comparative clinical studies evaluating the effectiveness of these rescue therapies are lacking. Therefore, we conducted a network meta-analysis to study the effectiveness of rescue therapies for SR ASUC. METHODS: Six randomized controlled trials and 15 cohort studies including 2,004 patients were analyzed...
July 9, 2024: Journal of Crohn's & Colitis
#4
EDITORIAL
Bram Verstockt
No abstract text is available yet for this article.
July 5, 2024: Journal of Crohn's & Colitis
#5
JOURNAL ARTICLE
Eleonora Franzè, Federica Laudisi, Claudia Maresca, Antonio Di Grazia, Andrea Iannucci, Teresa Pacifico, Angela Ortenzi, Giuseppe Sica, Elisabetta Lolli, Carmine Stolfi, Ivan Monteleone, Giovanni Monteleone
BACKGROUND AND AIM: Bromodomain-containing protein 4 (BRD4), one of the components of the bromodomain and extraterminal domain (BET) family, is a transcriptional and epigenetic regulator of cellular proliferation and cytokine production. In this study, we assessed whether BRD4 regulates the cytokine response in inflammatory bowel diseases (IBD). MATERIALS AND METHODS: BRD4 expression was analyzed in intestinal mucosal samples of patients with ulcerative colitis (UC), patients with Crohn's disease (CD), normal controls (CTRs), and mice with chemically-induced colitis by real-time PCR, Western blotting, and confocal microscopy...
July 2, 2024: Journal of Crohn's & Colitis
#6
JOURNAL ARTICLE
Akhilesh Swaminathan, Grace Mary Borichevsky, Chris Frampton, Anthony James Kettle, Laurent Peyrin-Biroulet, Corey Allan Siegel, Andrew Stewart Day, Richard Blair Gearry
INTRODUCTION: The disease severity index (DSI) encapsulates the inflammatory bowel disease (IBD) burden but requires endoscopic investigations. This study developed a non-invasive DSI using faecal calprotectin (DSI-fCal) and faecal myeloperoxidase (DSI-fMPO) instead of colonoscopy. METHODS: Adults with IBD were recruited prospectively. Baseline biomarker concentrations were used to develop DSI-fCal and DSI-fMPO, and these were correlated with the original DSI, IBD-symptoms, endoscopic activity, and quality-of-life (QoL)...
July 2, 2024: Journal of Crohn's & Colitis
#7
JOURNAL ARTICLE
Changqing Ma, Talin Haritunians, Anas K Gremida, Gaurav Syal, Janaki Shah, Shaohong Yang, Claudia Ramos Del Aguila de Rivers, Chad E Storer, Ling Chen, Emebet Mengesha, Angela Mujukian, Mary Hanna, Phillip Fleshner, David G Binion, Kelli L VanDussen, Thaddeus S Stappenbeck, Richard D Head, Matthew A Ciorba, Dermot P B McGovern, Ta-Chiang Liu
BACKGROUND & AIMS: Biomarkers that integrate genetic and environmental factors and predict outcome in complex immune diseases such as inflammatory bowel disease (IBD; including Crohn's disease [CD] and ulcerative colitis [UC]) are needed. We showed that morphologic patterns of ileal Paneth cells (Paneth cell phenotype [PCP]; a surrogate for PC function) is one such cellular biomarker for CD. Given the shared features between CD and UC, we hypothesized that PCP is also associated with molecular/genetic features and outcome in UC...
July 2, 2024: Journal of Crohn's & Colitis
#8
JOURNAL ARTICLE
Johan F K F Ilvemark, Rune Wilkens, Peter Thielsen, Anders Dige, Trine Boysen, Jørn Brynskov, Jacob T Bjerrum, Jakob B Seidelin
BACKGROUND AND AIMS: Reliable and easily accessible objective markers of disease activity to predict long-term treatment outcomes in severe ulcerative colitis (UC) are missing. We aimed to investigate if intestinal ultrasound (IUS) might predict long-term outcomes in hospitalized patients with severe UC treated with intravenous corticosteroids. METHODS: Hospitalized patients with severe UC and IUS inflammation (bowel wall thickness (BWT)>3.0mm) starting IV corticosteroids were recruited at three university hospitals in Denmark...
June 28, 2024: Journal of Crohn's & Colitis
#9
JOURNAL ARTICLE
Eric Prado, Cindy C Y Law, Catherine Rowan, Ali Osman, Emily Gore, David H Ballard, Daniel R Ludwig, Richard Tsai, Maté Gergely, Amine Geahchan, Bachir Taouli, Ghadi Abboud, Emre Altinmakas, Palak Rajauria, Jean-Frederic Colombel, Ryan C Ungaro, Parakkal Deepak
BACKGROUND & AIMS: The Lemann Index (LI), an endpoint to measure cumulative structural bowel damage in Crohn's disease (CD), has been recently updated and validated. We applied this to investigate predictors of bowel damage in a real-world cohort. METHODS: We performed a retrospective study (2008-2022) involving two tertiary referral IBD centers in the US. MR or CT enterographies were reviewed by study radiologists and endoscopy reports by study gastroenterologists, to calculate LI...
June 27, 2024: Journal of Crohn's & Colitis
#10
JOURNAL ARTICLE
Corey A Siegel, Victoria Rai, An Outtier, Severine Vermeire, Cindy C W Law, Bruce E Sands, Asim Abdulhamid, Richard Gearry, Josh McGuire, James O Lindsay, Remo Panaccione, Hagai Schweistein, Iris Dotan, Luca Scarallo, Anne Griffiths, Marla C Dubinsky
BACKGROUND: Clinical trial recruitment for patients with inflammatory bowel disease (IBD) has become more challenging over time. We aimed to develop recommendations for broadening IBD clinical trial eligibility to improve the inclusion of a more representative patient population in a more efficient timeline. METHODS: We applied the RAND/UCLA Appropriateness Method focused on broadening IBD clinical trial eligibility. A literature review was performed for 7 domains, each representing a different area related to trial recruitment...
June 22, 2024: Journal of Crohn's & Colitis
#11
(no author information available yet)
No abstract text is available yet for this article.
June 21, 2024: Journal of Crohn's & Colitis
#12
JOURNAL ARTICLE
Michelle V Prosberg, Sofie I Halkjær, Bobby Lo, Christina Bremerskov-Köser, Johan F K F Ilvemark, Jakob B Seidelin, Malene F Kristiansen, Anja Kort, Thomas Kallemose, Peter Bager, Flemming Bendtsen, Inge Nordgaard-Lassen, Hanne S Kapel, Helene Kringel, Christian M O Kapel, Andreas M Petersen
BACKGROUND AND AIMS: To demonstrate that administration of 7500 Trichuris suis ova every second week over 24 weeks would reduce the intestinal inflammation in moderate ulcerative colitis. METHODS: A single-centre, randomized, double-blinded, placebo-controlled, phase 2b clinical trial of 7500 Trichuris suis ova every two weeks for 24 weeks compared to placebo in moderate activity of ulcerative colitis (Mayo score 6-10) were performed. Primary outcome: Clinical remission...
June 20, 2024: Journal of Crohn's & Colitis
#13
EDITORIAL
Bram Verstockt
No abstract text is available yet for this article.
June 17, 2024: Journal of Crohn's & Colitis
#14
JOURNAL ARTICLE
Sandeep K Mundhra, Divya Madan, Rithvik Golla, Pabitro Sahu, Sudheer K Vuyyuru, Bhaskar Kante, Peeyush Kumar, David Matthew, Shubham Prasad, Manas Vaishnav, Mahak Verma, Shubi Virmani, Aditya Bajaj, Manasvani Markandey, Mukesh Kumar Ranjan, Umang Arora, Mukesh Kumar Singh, Govind K Makharia, Vineet Ahuja, Saurabh Kedia
INTRODUCTION: 30-40% patients with acute severe ulcerative colitis (ASUC) fail intravenous (IV) steroids requiring medical rescue therapy/colectomy. Low baseline albumin predicts steroid non-response, and exclusive enteral nutrition (EEN) has been shown to improve steroid response and albumin levels. Albumin infusion due to its anti-inflammatory and anti-oxidant properties might further improve steroid response in ASUC, which was evaluated in present study. METHODS: In this open-label randomized controlled trial, patients with ASUC were randomized in 1:1 ratio to albumin + standard of care (SOC) + EEN vs...
June 17, 2024: Journal of Crohn's & Colitis
#15
JOURNAL ARTICLE
Matthias Kelm, Lena Wagner, Anna Widder, Regina Pistorius, Johanna C Wagner, Nicolas Schlegel, Christian Markus, Patrick Meybohm, Christoph-Thomas Germer, Wolfgang Schwenk, Sven Flemming
BACKGROUND AND AIMS: Despite recent advancements in medical and surgical techniques in patients suffering from Crohn`s Disease (CD), postoperative morbidity remains relevant due to a long-standing, non-curable disease burden. As demonstrated for oncological patients, perioperative enhanced recovery concepts provide great potential to improve postoperative outcome. However, robust evidence about the effect of perioperative enhanced recovery concepts in the specific cohort of CD patients is lacking...
June 15, 2024: Journal of Crohn's & Colitis
#16
JOURNAL ARTICLE
Michel Adamina, Silvia Minozzi, Janindra Warusavitarne, Christianne Buskens, Maria Chaparro, Bram Verstockt, Uri Kopylov, Manasi Agrawal, Mariangela Allocca, Raja Atreya, Robert Battat, Dominik Bettenworth, Gabriele Bislenghi, Steven Ross Brown, Johan Burisch, María José Casanova, Wladyslawa Czuber-Dochan, Joline de Groof, Alaa El-Hussuna, Pierre Ellul, Catarina Fidalgo, Gionata Fiorino, Javier Gisbert, João Guedelha Sabino, Jurij Hanzel, Stefan Holubar, Marietta Iacucci, Nusrat Iqbal, Christina Kapizioni, Konstantinos Karmiris, Taku Kobayashi, Paulo Gustavo Kotze, Gaetano Luglio, Christian Maaser, Gordon Moran, Nurulamin Noor, Konstantinos Papamichail, Georgios Peros, Catherine Reenaers, Giuseppe Sica, Rotem Sigall-Boneh, Stephan R Vavricka, Henit Yanai, Tim Raine, Hannah Gordon, Pär Myrelid
This article is the second in a series of two publications on the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohn's disease and an update of prior ECCO guidelines...
June 15, 2024: Journal of Crohn's & Colitis
#17
JOURNAL ARTICLE
Hannah Gordon, Silvia Minozzi, Uri Kopylov, Bram Verstockt, Maria Chaparro, Christianne Buskens, Janindra Warusavitarne, Manasi Agrawal, Mariangela Allocca, Raja Atreya, Robert Battat, Dominik Bettenworth, Gabriele Bislenghi, Steven Ross Brown, Johan Burisch, María José Casanova, Wladyslawa Czuber-Dochan, Joline de Groof, Alaa El-Hussuna, Pierre Ellul, Catarina Fidalgo, Gionata Fiorino, Javier Gisbert, João Guedelha Sabino, Jurij Hanzel, Stefan Holubar, Marietta Iacucci, Nusrat Iqbal, Christina Kapizioni, Konstantinos Karmiris, Taku Kobayashi, Paulo Gustavo Kotze, Gaetano Luglio, Christian Maaser, Gordon Moran, Nurulamin Noor, Konstantinos Papamichail, Georgios Peros, Catherine Reenaers, Giuseppe Sica, Rotem Sigall-Boneh, Stephan R Vavricka, Henit Yanai, Pär Myrelid, Michel Adamina, Tim Raine
No abstract text is available yet for this article.
June 15, 2024: Journal of Crohn's & Colitis
#18
JOURNAL ARTICLE
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, Geert R D'Haens, Julian Panés, Andres J Yarur, Douglas C Wolf, Timothy Ritter, Stefan Schreiber, John C Woolcott, Irene Modesto, Michael Keating, Kevin Shan, Joseph Wu, Michael V Chiorean, Filip Baert, Marla C Dubinsky, Martina Goetsch, Silvio Danese, Brian G Feagan
BACKGROUND AND AIMS: Etrasimod is an oral, once daily, selective sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis [UC]. This subgroup analysis evaluated the efficacy and safety of etrasimod 2 mg once daily vs placebo by prior biologic/Janus kinase inhibitor [bio/JAKi] exposure in ELEVATE UC 52 and ELEVATE UC 12. METHODS: Pre-defined efficacy endpoints were assessed at Weeks 12 and 52 in ELEVATE UC 52 and Week 12 in ELEVATE UC 12 in bio/JAKi-naïve and -experienced patients, and at Week 12 [pooled] based on prior advanced therapy exposure mechanism...
June 15, 2024: Journal of Crohn's & Colitis
#19
JOURNAL ARTICLE
Neeraj Narula, Hasan Hamam, Jasmine Liu, Emily C L Wong, John K Marshall, Vipul Jairath, Stephen B Hanauer, Walter Reinisch, Parambir S Dulai
INTRODUCTION: It is unclear if steroid tapering protocols can impact clinical trial outcomes in ulcerative colitis (UC), particularly fixed versus adaptive steroid tapering. Fixed steroid tapering involves incremental dose decreases at prespecified intervals and adaptive steroid tapering utilizes investigator discretion as determined by the patient's response. METHODS: In this post-hoc analysis from six clinical trials of UC (VARSITY, ACT 1, PURSUIT, GEMINI1, OCTAVE and ULTRA2), responders to induction therapy with baseline corticosteroid use were considered as the primary population of interest...
June 13, 2024: Journal of Crohn's & Colitis
#20
JOURNAL ARTICLE
Silvio Danese, Axel Dignass, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Isabel Redondo, Richard Moses, Sebastian Maier, Theresa Hunter Gibble, Nathan Morris, Catherine Milch, Maria T Abreu
BACKGROUND AND AIMS: Ulcerative colitis (UC), a chronic inflammatory bowel disease, may manifest with symptoms of increased stool frequency (SF), rectal bleeding (RB), bowel urgency (BU), abdominal pain (AP), and fatigue. Mirikizumab, an anti-IL-23p19 antibody, demonstrated efficacy and safety in patients with moderately to severely active UC in the LUCENT Phase 3 trials. We evaluated mirikizumab's efficacy in achieving symptom control and time to symptom improvement during induction, maintenance of sustained symptom control, "comprehensive symptom control", defined according to a combination of individual patient-reported outcomes, and prognostic baseline indicators of early symptomatic remission at week 4...
June 13, 2024: Journal of Crohn's & Colitis
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 